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Objectives. The aim of this prospective cohort, multicentre study was to assess the eﬀect of coadministrating ezetimibe 10mg/day
with an ongoing statin on the estimated risk for Cardiovascular (CVD) mortality in patients with persistently elevated LDL-C
after statin monotherapy. Methods. The Systematic Coronary Risk Evaluation (SCORE) function was used to estimate the 10-
year risk for cardiovascular mortality at baseline and 6 weeks. Primary outcome measures were absolute and percent changes in
estimated Coronary Heart Disease (CHD) Mortality Risk, and general CVD Mortality Risk (Total CVD Mortality Risk). Results.
825 patients were included in the analysis. Mean (SD) age was 62 (10.5) years and 62.3% were males. The mean (SD) estimated
Total CVD Mortality Risk decreased from 0.068 (0.059) at baseline to 0.053 (0.046) at 6 weeks (RR = 0.77; 95% CI:0.689–0.867),
while the estimated CHD Mortality Risk decreased from 0.047 (0.040) at baseline to 0.034 (0.029) at 6 weeks (RR = 0.72; 95%
CI:0.624–0.826). Conclusions. Co-administration of ezetimibe with a statin is eﬀective in signiﬁcantly reducing the estimated risk
for cardiovascular mortality as measured by the SCORE model.
1.Introduction
Cardiovascular disease is the major cause of mortality
in Canada, accounting for one-third of all deaths, with
an incidence expected to increase within the next decade
[1]. Increased serum cholesterol, particularly low-density
lipoprotein cholesterol (LDL-C), is directly associated with
an increased risk for cardiovascular disease (CVD) [2–
5]. Initiation of lipid-lowering pharmacologic intervention
for the management of hypercholesterolaemia is generally
dependent on the individual patient’s estimated risk for
cardiovascular events [3, 6, 7]. Ultimately, the aim of lipid-
lowering treatment is to eﬀectively reduce the individual
patient’s risk for CVD, thus decreasing related mortality,
morbidity and burden of illness. A cardiovascular risk
prediction model was developed by the SCORE (Systemic
COronary Risk Evaluation) project group in accordance to
the recommendations from the Second Joint Task Force
of European and other Societies on Coronary Prevention
[7]. The SCORE model is based on pooled data from 12
European cohort studies, including data on over 205,000
individuals and representing 2.7 million person-years of
followup.Themodelpredictstheindividual’s10-yearriskfor
fatal cardiovascular events on the basis of age, gender, smok-
ingstatus,systolicbloodpressure(SBP),andtotalcholesterol
(TC). The total SCORE risk is further subdivided into the
riskforfatalCHDandothernon-CHDcardiovasculardeath.
First-line pharmacotherapy for the management of
hypercholesterolaemia typically involves lipid-lowering
treatment with statins [3, 8, 9]. Despite the eﬀectiveness
of statins in reducing serum LDL-C levels, the results of
large clinical trials and epidemiological studies have shown2 Advances in Preventive Medicine
that a signiﬁcant proportion of patients does not achieve
target LDL-C levels while on treatment with statins [10–12].
For these patients who remain at increased risk for CVD,
combination therapy with additional agents inhibiting
cholesterol absorption or bile acid reabsorption, or conco-
mitant use of niacin is recommended by the Canadian
Cardiovascular Society [9]. Ezetimibe is a lipid-lowering
compound that inhibits cholesterol absorption from the
small intestine without aﬀecting the uptake of triglycerides
(TG) or fat-soluble vitamins [13]. Co-administration of
ezetimibe with statins has been shown to be a potent
dual-target strategy, providing enhanced reduction of
LDL-C and improvement of the lipid proﬁle over statin
monotherapy [14–19], while potentially decreasing the
risk of adverse events associated with high-dose statins
through moderating the dose of co-administrated statin
[20–22].
The Ezetrol Add-On study was a multicentre, prospec-
tive, Canadian cohort study involving 837 patients who had
not achieved target LDL-C levels while on statin mono-
therapy [23]. The results of this study showed that addition
of ezetimibe to the patients’ existing statin regimen for six
weeks was eﬀective in signiﬁcantly reducing LDL-C by a
mean of 30%, from 3.43 to 2.83mmol/L. The purpose of the
current analysis was to assess the change in predicted risk for
fatal CVD as estimated by the SCORE model in the Ezetrol
Add-On cohort of patients.
2. Methods
2.1.StudyDesign. TheEzetrolAdd-On-Studywasaprospec-
tive, single-cohort, open-label study conducted in the oﬃces
of Canadian general practitioners. Study design details are
published elsewhere [23].
In brief, all patients were treated with ezetimibe 10mg/
day co-administered with their existing statin regimen for
six weeks. There were no limitations on the type or dose of
statin used other than maintaining the same regimen for the
duration of the study. The ﬁnal study assessment took place
six weeks (±4 days) after the baseline visit. Patients provided
written informed consent prior to participation in the study.
The study was approved by two independent ethics review
boards (IRB services in Aurora, Ontario and the College of
Physicians and Surgeons of Alberta [CPSA]).
2.2. Sample Selection. Patients were enrolled by 221 par-
ticipating physicians. Eligible patients were ≥18 years old
with conﬁrmed hypercholesterolaemia deﬁned as LDL-C
≥2.5mmol/L for patients at high 10-year coronary artery
disease (CAD) risk, LDL-C ≥3.5mmol/L for moderate risk
patients and LDL-C ≥4.5mmol/L for low-risk patients
[8].
Patients were excluded from the study if they had any
condition that would render the patient unable to complete
the study or for which study participation would produce
signiﬁcant risk or not be in the best interest of the patient
[23]. Concomitant use of any medications that may interact
negatively with statins or ezetimibe or aﬀect the patient’s
serum lipid levels was prohibited.
Patients treated with cardiovascular medications were
included in the study provided that they were on a stable
medication regimen for at least 4 weeks prior to study entry
and remained on the same regimen for the duration of the
study.
2.3. Outcome Measures. Estimated 10-year risks for fatal
cardiovascular event in general CVD (Total CVD Mortality
Risk) and for CHD (CHD Mortality Risk) were estimated
using the SCORE function. The SCORE risk estimation is
based on the individual’s age, gender, smoking status, TC,
and SBP [7]. The Total CVD-Risk estimate is comprised of
the risk for fatal CHD (CHD Mortality Risk) and the risk
of fatal non-CHD cardiovascular events. The CHD Mortality
Risk and Total CVD Mortality Risk for each subject were
estimated at baseline and at six weeks of followup. The
primary outcome measures of the analysis were the absolute
and percent changes in estimated CHD Mortality Risk and
Total CVD Mortality Risk from baseline to the six-week
follow-up visit.
2.4. Statistical Methods. The intention-to-treat (ITT) prin-
ciple, including all study patients completing the six-week
visit assessment, regardless of compliance with the study
protocol, was applied in the analysis. Patients who were lost
to followup and did not return for the six-week assessment
could not be included in the analysis. The statistical signiﬁ-
cance of the absolute and percent changes in estimated CHD
Mortality Risk and Total CVD Mortality Risk were assessed
with the Student’s t-test for paired samples. The analysis was
conducted for the study sample as a whole and stratiﬁed by
the presence of hypertension, type II diabetes mellitus, the
metabolic syndrome and smoking. The metabolic syndrome
was deﬁned according to the American Heart Association
(AHA) criteria published at the time of the study [24],
while hypertension was based on the diagnosis of the
treating physician. Current smoking status was ascertained
by the treating physician during the screening visit and was
assumed to be unchanged during the course of the study.
The number of CHD and total CVD deaths per 100,000 at
baseline and six weeks was estimated on the basis of the risk
estimates. Relative risk (RR) estimates with 95% conﬁdence
intervals (CI) were used to assess the precision and statistical
signiﬁcance eﬀect of the change in the estimated CHD and
total CVD mortality rates.
3. Results
A total of 1,141 patients were screened between November
2003 and April 2005, among which 953 (83.5%) fulﬁlled
the study inclusion criteria and were enrolled in the study.
Of the 953 patients enrolled, 825 (86.6%) completed the
six-week follow-up with suﬃcient data for SCORE risk
estimation at baseline and at six weeks. There were 128
patientswhodiscontinuedfromthestudypriortothefollow-
up assessment and cannot be included in this analysis since
change in the outcome parameters could not be computed.
Theseincluded50(5.2%)patientswhowerelosttofollowup,
45 (4.7%) who were withdrawn by the study investigatorsAdvances in Preventive Medicine 3
Table 1: Modiﬁable SCORE risk factors at baseline and ﬁnal (6-week) assessments.
Systolic Blood Pressure (mmHg) Total Cholesterol (mmol/L)
Comorbidity/Risk Factor∗ Baseline 6-week Absolute Change Baseline 6-week Absolute Change
Mean (SD) Mean (SD) Mean (SD) 95% CI Mean (SD) Mean (SD) Mean (SD) 95% CI
All Patients (N = 825) 132.0 (14.0) 128.2 (13.7) −3.75 (13.3) −2.84, −4.66 5.60 (1.00) 4.40 (1.00) −1.18 (0.89) −1.12, −1.24
Hypertension (N = 423) 138.6 (13.3) 132.0 (12.9) −6.59 (14.1) −5.25, −7.94 5.51 (0.92) 4.36 (0.98) −1.14 (0.91) −1.05, −1.23
Diabetes (N = 342) 132.7 (13.7) 129.2 (13.9) −3.49 (13.5) −2.06, −4.93 5.63 (1.11) 4.51 (1.08) −1.26 (0.94) −1.16, −1.36
Metabolic Syndrome
(N =395)
136.0 (13.9) 131.7 (13.0) −4.27 (13.9) −2.89, −5.64 5.62 (0.99) 4.35 (1.04) −1.27 (0.97) −1.17, −1.37
Current Smokers
(N = 188)
132.1 (14.4) 126.6 (13.6) −5.50 (13.1) −3.62, −7.38 5.67 (1.18) 4.34 (0.92) −1.33 (0.97) −1.47, −1.19
∗Patients may have more than one comorbid condition.
because they changed or stopped their statin treatment, 19
(2.0%) who withdrew due to adverse events, 2 (0.2%) who
withdrew consent prior to initiation of treatment, and 12
(1.3%) who were missing data for SCORE estimation.
The mean (SD) age of the study sample was 62 (10.5)
years with a range between 21 and 89 years, while 62.3%
of the patients were male. The most frequently reported
comorbidities and risk factors were hypertension (n = 423,
51.3%), type II diabetes mellitus (n = 342, 41.5%), the
metabolicsyndrome(n=395,47.9%),andsmoking(n=188,
22.8%). Furthermore, 489 (59.3%) patients had a known
family history of CVD and 375 (45.5%) patients of CAD.
For the 825 patients included in the analysis, the distribution
of statins used during the study period was atorvastatin
in 412 (50.5%), followed by simvastatin in 162 (19.6%),
rosuvastatin in 118 (14.3%), pravastatin in 102 (12.4%),
l o v a s t a t i ni n2 4( 2 . 9 % ) ,a n dﬂ u v a s t a t i ni n7( 0 . 8 % )p a t i e n t s .
Prior to study enrolment, 328 (39.8%) patients were treated
with a moderate or high statin dose, deﬁned as 40mg/day or
80mg/day depending on the speciﬁc statin.
The changes in the modiﬁable risk factor variables
applied in the SCORE calculations are shown in Table 1.
After six weeks of treatment, a signiﬁcant mean decrease in
SBP from 132.0 to 128.2mmHg was observed (P < .001)
with the largest absolute decrease of −6.59mmHg (95% CI:
−5.25 to −7.94) observed in patients with hypertension. A
signiﬁcant decrease was similarly observed for TC, which
decreased from 5.60 to 4.40mmol/L (P < .001). The largest
absolute TC decrease of −1.33mmol/L (95% CI: −1.47 to
−1.19) was observed in these patients who were smokers at
the time of the study (Table 1).
At baseline, the mean 10-year estimated CHD Mortality
Risk for the study sample was 0.047 (47/1,000 patients),
which decreased to 0.034 (34/1,000 patients) after six weeks
of treatment (Table 2). Both the mean absolute decrease of
−0.013 (95% CI: −0.015 to −0.012), or 13/1,000 patients,
and the mean percent decrease of −0.254 (95% CI: −0.271
to −0.238), were statistically signiﬁcant (P < .001). A similar
signiﬁcant decrease in estimated CHD Mortality Risk was
observed for all four patient subgroups analyzed (Table 2).
The highest absolute and percent change was observed for
smokers with a mean absolute decrease in CHD SCORE of
0.018 and mean percent decrease of −30.3%.
After six weeks of treatment, a statistically signiﬁcant
decrease in the mean estimated Total CVD Mortality Risk
was also observed (P < .001). For the total study sample,
the mean estimated Total CVD Mortality Risk decreased
from 0.068 (68/1,000 patients) at baseline to 0.053 (53/1,000
patients) after six weeks of treatment (Table 3). Both the
mean absolute and percent decrease of −0.015 (15/1,000
patients) (95% CI: −0.017 to −0.013) and −0.198 (95% CI:
−0.215 to −0.181), respectively, were statistically signiﬁcant
(P < .001). The highest decrease in estimated Total CVD
Mortality Risk was observed for the subgroups of patients
with hypertension and smokers.
The estimates of 10-year CHD mortality based on the
SCORE risk at the baseline and six-week assessments are
summarized in Figure 1. The number of estimated CHD
deaths per 100,000 person-years decreased from 470 to 337
after combination treatment of ezetimibe with the current
statin for six weeks. This is equivalent to a 28% reduction
in the overall estimated risk for fatal CHD (RR = 0.72; 95%
CI:0.624to0.826).Similardecreasesintheestimated10-year
CHDmortalitywereobservedforpatientswithhypertension
(RR = 0.69; 95% CI: 0.601 to 0.784), diabetes (RR = 0.71;
95% CI: 0.610 to 0.825), the metabolic syndrome (RR =
0.70; 95% CI: 0.603 to 0.801), and for smokers (RR = 0.67;
95% CI: 0.591 to 0.769). The estimated eﬀect of treatment
on total CVD mortality is summarized in Figure 2. These
results indicate that, in this cohort of patients, the estimated
number of CVD deaths decreased from 685 to 530 per
100,000 person-years for an estimated relative risk of 0.77
(95% CI: 0.689 to 0.867). Similar signiﬁcant risk reductions
were observed for the patient subgroups analyzed.
A low incidence (5.6%) of predominantly mild adverse
events with probable or deﬁnite causal association to eze-
timibe was observed in the Ezetrol Add-On study. The most
frequently reported adverse events were constipation (0.7%),
diarrhea(0.4%),dizziness(0.4%),ﬂatulence(0.3%),myalgia
(0.3%), headache (0.3%), dyspepsia (0.2%), nausea (0.2%),
fatigue (0.2%), and arthralgia (0.2%). There were no serious
adverse events reported in the study.4 Advances in Preventive Medicine
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4. Discussion
An important proportion of patients with hypercholes-
terolaemia do not achieve target cholesterol levels with
statin monotherapy [10–12]. In these patients, combination
of ezetimibe with low-dose statin has been shown to
be eﬀective in improving the lipid proﬁle, providing an
additional 20% to 25% reduction in low density lipoprotein
cholesterol (LDL-C) compared to statin monotherapy [9,
25], while potentially protecting from the risk of adverse
events associated with high-dose statins through moderating
the dose of co-administrated statin [20–22]. To date, the
direct eﬀect of ezetimibe co-administered with a statin
on the risk of cardiovascular mortality from a population
perspective has not been reported. The current study applied
the SCORE model to estimate the change in 10-year risk
for cardiovascular mortality in patients that had persistent
elevated LDL-C while on statin monotherapy, upon co-
administration of ezetimibe with their existing statin regi-
men. The SCORE cohort consists of 205,178 patients with
more than 2.7 million person-years of followupand a total of
7,934 observed cardiovascular deaths (5,652 from coronary
heart disease) [7]. The sample size, high number of events,
anddurationoffollowupofthecohortensurehighpredictive
validity of the model.
The results of the current study indicate that co-
administration of ezetimibe 10 mg/day to any statin regimen
is eﬀective in reducing the estimated 10-year CHD and CVD
mortalities by 25% and 20%, respectively, based on the
SCOREriskmodel.ThecalculationofmortalityriskwiththeAdvances in Preventive Medicine 5
Table 2: CHD SCORE at baseline and ﬁnal (6-week) assessments.
Patient Group CHD SCORE
Baseline 6 weeks Absolute Change Percent Change
Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
Hypertension 0.054 0.044 0.050 0.058 0.037 0.030 0.034 0.040 −0.017 0.023 −0.019 −0.015 −0.280 0.243 −0.304 −0.257
Diabetes 0.041 0.034 0.037 0.044 0.029 0.025 0.026 0.032 −0.012 0.017 −0.014 −0.010 −0.264 0.244 −0.290 −0.238
MS∗ 0.047 0.040 0.043 0.051 0.033 0.028 0.030 0.035 −0.014 0.020 −0.016 −0.012 −0.273 0.250 −0.298 −0.248
Smoking 0.056 0.050 0.049 0.063 0.038 0.034 0.033 0.042 −0.018 0.023 −0.021 −0.014 −0.303 0.211 −0.334 −0.273
Total 0.047 0.040 0.044 0.050 0.034 0.029 0.032 0.036 −0.013 0.020 −0.015 −0.012 −0.254 0.243 −0.271 −0.238
∗MS: metabolic syndrome.
Table 3: Total CVD SCORE at baseline and ﬁnal (6-week) assessments.
Patient Group Total CVD SCORE
Baseline 6 weeks Absolute Change Percent Change
Mean SD
95% CI Mean SD 95% CI Mean SD 95% CI Mean SD 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
Hypertension 0.080 0.064 0.074 0.086 0.059 0.048 0.054 0.063 −0.021 0.032 −0.024 −0.018 −0.230 0.243 −0.253 −0.207
Diabetes 0.061 0.051 0.055 0.066 0.047 0.041 0.042 0.051 −0.014 0.024 −0.017 −0.012 −0.200 0.255 −0.227 −0.173
MS∗ 0.069 0.059 0.063 0.075 0.052 0.045 0.047 0.056 −0.017 0.028 −0.020 −0.014 −0.212 0.257 −0.238 −0.187
Smoking 0.077 0.070 0.067 0.087 0.056 0.051 0.049 0.063 −0.021 0.030 −0.025 −0.016 −0.254 0.214 −0.284 −0.223
Total 0.068 0.059 0.065 0.072 0.053 0.046 0.050 0.056 −0.015 0.028 −0.017 −0.013 −0.198 0.249 −0.215 −0.181
∗MS: metabolic syndrome.
SCORE model is based on changes in the lipid proﬁle as well
as changes in SBP and smoking status. Although a change
of smoking status is unlikely to occur within six weeks, it
cannot be excluded. However, its impact on cardiovascular
risk within six weeks is likely limited. Conversely, the change
in SBP may have aﬀected the overall risk estimate. In the
current study the mean change in SBP between baseline
and six weeks of followup was −3.75mmHg. In fact the
change in SBP observed for the total study sample would
produce a 6.5% change in estimated CHD risk (RR = 0.935),
whereas the observed change in total cholesterol would
produce a 24.9% change in the estimated CHD risk (RR
= 0.75). These results are in agreement with recent studies
showing that co-administration of ezetimibe with statins
provides an additional improvement in serum LDL-C and
overall lipid proﬁle in patients with inadequate lipid control
while on statin monotherapy [14–19]. Furthermore, recent
reports indicate that ezetimibe exerts pleiotropic eﬀects on
cardiovascular function which are similar [26]o ri m p r o v e d
[27, 28] compared to statin monotherapy, while additional
trials are ongoing which will further analyze the impact of
ezetimibe on these eﬀects [29, 30].
A number of features in our study design render its
results relevant to the real-life setting and generalizable to
the target population; patients were recruited without any
limitations in their statin regimen and continued receiving
it in combination with ezetimibe during the six-week study
follow-up period. Furthermore, physicians were instructed
to adhere to their routine care for the management of their
patients, and to the product monograph for ezetimibe treat-
ment. Finally, generalization of our study results to the real-
life setting is further supported because the inclusion and
exclusion criteria of the current study were deﬁned in order
to represent the patients treated with ezetimibe in routine
clinical practice and because all patients were included in the
analysis,regardlessofcompliancewithtreatment.Asaresult,
the demographic proﬁle and distribution of statins used by
the subjects in our study were similar to those reported in
population-basedepidemiologicalCanadianstudies[10,31].
Potential limitations of the current study are related to
the single cohort design. However, this was an observational
study with primary objective, the change in estimated 10-
year CVD mortality risk during ezetimibe add-on to the
existing statin regimen, and not the comparison of its
eﬀectiveness to a diﬀerent treatment. Furthermore, taking
into consideration that hypercholesterolaemia in all patients
wasinadequatelycontrolledwhileonasteadyandestablished
statin regimen, it is unlikely that maintenance on the current
statin regimen would incur any further lipid changes, which
serves as an internal control. Another potential limitation
of the current study may involve the use of the SCORE
model in a North American population. The SCORE model
was developed in Europe and may reﬂect speciﬁc risk
factor eﬀects of the European population. However, the
SCORE model was selected for the current study because
it speciﬁcally produces estimates of mortality and not CVD6 Advances in Preventive Medicine
in general. In addition, the wide range of European-based
ethnic origins in the Canadian population renders the
use of the SCORE model even more relevant. Finally, the
generalizability of our results to the target population and
the emulation of the real-life setting achieved by the study
design are important strengths of the current study, while
the use of a validated model as the outcome measure allows
reproducibility and comparisons across diﬀerent studies and
populations.
5. Conclusions
For patients who remain at increased risk for cardiovascular
morbidity or mortality due to persistent hypercholestero-
laemia while on statin monotherapy, co-administration of
ezetimibe with a statin is eﬀective in signiﬁcantly reducing
the estimated long-term risk for cardiovascular mortality.
However, additional population studies to conﬁrm the long-
term eﬀect of combination therapy with ezetimibe and
statins on cardiovascular mortality are required.
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